AMYRA Successfully Demonstrates a New Therapeutic Paradigm for Gluten-Related Disorders in a First-in-Human Study
October 23, 2024 04:00 ET
|
AKAMPION
Lead product AMYNOPEP achieves proof-of-principle in exploratory clinical studyAMYNOPEP is the first and only gluten-digesting enzyme combination that supports and enhances the activity of critical...
Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
September 24, 2024 08:00 ET
|
Barinthus Biotherapeutics
Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
Entero Therapeutics Signs Letter of Intent to License and Commercialize Remote Patient and Machine Vision Clinical Trial Management Platform from Data Vault Holdings
September 10, 2024 07:00 ET
|
Entero Therapeutics, Inc.
BOCA RATON, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
Canadian Post Secondary Institutions Fall Short on Gluten-Free Accommodations
August 27, 2024 15:56 ET
|
Celiac Canada
Toronto, ON, Aug. 27, 2024 (GLOBE NEWSWIRE) -- A recent survey conducted by Celiac Canada reveals that Canadian universities and colleges are not providing adequate gluten-free accommodations on...
Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results
August 08, 2024 08:00 ET
|
Barinthus Biotherapeutics
Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results
Entero Therapeutics’ Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program
July 31, 2024 07:00 ET
|
Entero Therapeutics, Inc.
BOCA RATON, Fla., July 31, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
Gluten Free Products Market Surges to USD 8.73 Billion by 2031, Propelled by 7.20% CAGR - Verified Market Research®
July 18, 2024 10:00 ET
|
Verified Market Research
Lewes, Delaware, July 18, 2024 (GLOBE NEWSWIRE) -- The Global Gluten Free Products Market Size is projected to grow at a CAGR of 7.20% from 2024 to 2031, according to a new report published by...
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
June 12, 2024 16:01 ET
|
Barinthus Biotherapeutics
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
Entero Therapeutics to Present Corporate Update at 2024 BIO International Convention
May 22, 2024 07:00 ET
|
Entero Therapeutics, Inc.
BOCA RATON, Fla., May 22, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (formerly First Wave BioPharma, Inc.) (Nasdaq: ENTO) (“Entero” or the “Company”), a late clinical-stage...
Entero Therapeutics Presents Two Posters on Celiac Disease Research at the 2024 Digestive Disease Week (DDW) Conference
May 20, 2024 07:00 ET
|
Entero Therapeutics, Inc.
BOCA RATON, Fla., May 20, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...